Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly video chats with a nurse may help tame type 2 diabetes

NCT ID NCT07793292

Disease control Sponsor: Sultan Qaboos University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether adding a nurse-led telehealth education program to usual diabetes care improves blood sugar control, medication habits, and quality of life in adults with type 2 diabetes in Oman. About 160 participants will be randomly assigned to either receive weekly 20-30 minute telehealth sessions for 24 weeks or continue with usual care alone. Researchers will measure changes in HbA1c, a blood test reflecting average blood sugar over the past few months, along with questionnaires on medication attitudes and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telehealth educational intervention delivered by a trained nurse
What this could lead to
If it works, this could offer a practical way to improve blood sugar control and quality of life for people with type 2 diabetes, especially in regions where access to in-person care is limited.
What could go wrong
The trial is relatively small and tests a behavioral program, not a drug. Results may vary by individual, and the benefit might not be large enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following: * Omani national aged 18 years or older. * Confirmed type 2 diabetes mellitus (T2DM) documented in the medical record. * Prescribed at least one glucose-lowering medication and receiving treatment for at least 3 months before enrollment. * Most recent clinically valid HbA1c, or screening HbA1c when appropriate, 7.5% or higher. * Access to an internet-enabled smartphone, tablet, or computer and ability to participate in video- or audio-supported telehealth sessions. * Able to understand Arabic or English sufficiently to provide informed consent and participate in study procedures, and able to complete the validated Arabic Oman version of the medication-adherence questionnaire. * Willingness to be randomized and availability for 6 months of follow-up. Exclusion Criteria: * Type 1 diabetes, gestational diabetes, or another diabetes type for which the intervention and outcome plan is not appropriate. * Current pregnancy or planned pregnancy during follow-up. * Severe cognitive impairment, active psychosis, or another condition preventing informed consent or meaningful participation. * Acute medical instability or hospital admission at recruitment. * Participation in another interventional study that could materially affect trial outcomes. * Inability to use telehealth even with reasonable assistance or absence of a private and safe setting for sessions. * Another clinical or ethical reason identified by the treating clinician or principal investigator that makes participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Medication Adherence type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sultan Qaboos University Hospital

    Muscat, Al Khoud, 123, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.